查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
支氣管炎治療的全球市場:現狀分析與預測(2021年～2027年)
市場調查報告書
商品編碼
1096539

支氣管炎治療的全球市場:現狀分析與預測(2021年～2027年)

Bronchitis Treatment Market: Current Analysis and Forecast (2021-2027)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球支氣管炎治療的市場規模在預測期間(2021年～2027年)中預計將以約5％的年複合成長率成長。

哮喘、慢性阻塞性肺病和肺癌等呼吸道疾病的患病率不斷上升，加上人口老齡化的加劇，預計將推動對支氣管炎治療的需求，並推動支氣管炎治療市場的增長。預計吸煙人口的迅速增加也將增加對支氣管炎治療的需求。

本報告提供全球支氣管炎治療市場的相關調查，提供市場洞察，市場趨勢，競爭模式，企業概要等全面性資訊。

目錄

第1章 市場簡介

  • 市場定義
  • 限制
  • 相關利益者
  • 報告所使用的貨幣

第2章 調查方法或假設

  • 支氣管炎治療市場調查流程
  • 支氣管炎治療市場調查手法
  • 預測方法
  • 受訪者簡介
  • 支氣管炎治療市場調查的主要目的

第3章 市場摘要

第4章 摘要整理

第5章 支氣管炎治療市場上COVID-19影響

第6章 支氣管炎治療市場收益(10億美元)(2019年～2027年)

第7章 市場洞察:各類型

  • 急性支氣管炎
  • 慢性支氣管炎

第8章 市場洞察:各類藥物

  • 抗生素
  • 抗發炎藥
  • 支氣管擴張藥
  • 其他

第9章 市場洞察:各流通管道

  • 醫院藥局
  • 零售藥局
  • 其他

第10章 市場洞察:各地區

  • 北美
    • 美國
    • 加拿大
    • 其他的北美
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他的亞太地區
  • 其他

第11章 支氣管炎治療市場動態

  • 推動市場要素
  • 市場課題
  • 影響分析

第12章 支氣管炎治療市場機會

第13章 支氣管炎治療市場趨勢

第14章 需求與供給面的分析

  • 需求面分析
  • 供給面分析

第15章 價值鏈分析

第16章 競爭模式

  • 競爭情形
    • 波特的五力分析

第17章 公司概要

  • AstraZeneca PLC
  • Novartis AG
  • GlaxoSmithKline PLC
  • Dr. Reddy's Laboratories Ltd
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Melinta Therapeutics
  • Lupin Limited
  • Cadila Healthcare Limited

第18章 免責聲明

簡介目錄
Product Code: UMHE21863

The global bronchitis treatment market is expected to witness a CAGR of around 5% during the forecast period (2021-2027). The rising prevalence of respiratory diseases such as asthma, COPD, and lung cancer, among others coupled with rising geriatric population is expected to drive the demand for effective bronchitis treatment. According to the world health organization (WHO), around 262 million people suffer from asthma, and nearly 3 million people die from chronic obstructive pulmonary disease (COPD). Additionally, Bronchitis is when the tubes that carry air to your lungs, called the bronchial tubes, get inflamed and swollen.

AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Dr. Reddy's Laboratories Ltd, Sanofi SA, Boehringer Ingelheim International GmbH, Pfizer Inc., Melinta Therapeutics, Lupin Limited, Cadila Healthcare Limited Services are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

"Amongst Type, Acute Bronchitis category to witness the fastest growth during the forecast period"

Based on type, the market is classified into acute bronchitis and chronic bronchitis. Amongst them, in 2020, the acute bronchitis category dominated the market and is expected to maintain its dominance throughout the forecast period. Acute bronchitis is an infectious viral infection that causes inflammation of the bronchial tubes. These tubes are the airways that carry air into your lungs. When these tubes get infected, they swell mucus (thick fluid) forms inside them. This narrows the airways, making it harder for breath-dependent patients. Furthermore, smoking is the main cause of chronic bronchitis. Therefore, an upsurge in the smoking populace is further expected to increase the need for bronchitis treatment. For instance, according to the Centers for Disease Control and Prevention (CDC), Nearly 40 million U.S. adults still smoke cigarettes, and an estimated 2.55 million middle and high school students use at least one tobacco product, including e-cigarettes.

"Amongst Drug Class, Bronchodilator category is expected to witness significant growth in the Bronchitis treatment market"

Based on drug class, the market is bifurcated into antibiotics, anti-inflammatory, bronchodilator, and others. Among them, in 2020, the bronchodilator category dominated the market and is expected to maintain its dominance throughout the forecast period. This is mainly due to the rising prevalence of chronic obstructive pulmonary disease (COPD), smoking, pollution, respiratory diseases, etc. According to the World health organization (WHO), Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019.

"Amongst Distribution Channel, Hospitals Pharmacies category is expected to witness significant growth in the Bronchitis treatment market"

Based on distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, and others. In 2020, the hospitals and clinics category accounted for the majority share during the forecast period. This can be ascribed to the fact that hospitals and clinics are the first step in any disease diagnosis. In addition, the growth of this market segment includes increased incidences of respiratory diseases, growth in the geriatric population, COPD, bronchitis, asthma, smoking, and rising air pollution all over the world. Additionally, smoking is the major reason for complications of bronchitis. Furthermore, according to the office of diseases prevention and health promotion (ODPHP), Currently, more than 25 million people in the United States have asthma. Approximately 14.8 million adults have been diagnosed with COPD, and approximately 12 million people have not yet been diagnosed. Furthermore, governments across the works are investing heavily in the development and improvement of healthcare infrastructure. Moreover, rising patient footfall in hospitals owing to ease of accessibility to most healthcare services in one place is likely to boost the segment growth.

"North America to witness significant growth during the forecast period"

For a better understanding of the market adoption of the Bronchitis treatment industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America); Europe (Germany, United Kingdom, France, Spain, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Rest of Asia-Pacific); and the Rest of World. In 2020. North America held an extensive market share owing to the increasing prevalence of respiratory diseases, growth in the geriatric population, COPD, bronchitis, asthma, smoking, and rising air pollution coupled with the rising geriatric population in the region. According to the US Census Bureau analysis, the elderly population is expected to nearly double in the next 25 years. In addition, according to World Population Ageing, in 2019, the elderly population of North America was 59.9 million which is expected to reach 96.2 million by 2050.

Reasons to buy this report:

  • The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
  • The report presents a quick review of overall industry performance at one glance.
  • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
  • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
  • The study comprehensively covers the market across different segments.
  • Deep dive regional level analysis of the industry.

Customization Options:

The Bronchitis treatment market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Limitation
  • 1.3. Stakeholders
  • 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Bronchitis treatment Market
  • 2.2. Research Methodology of the Bronchitis treatment Market
  • 2.3. Forecasting Method
  • 2.4. Respondent Profile
  • 2.5. Main Objective of the Bronchitis treatment Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 BRONCHITIS TREATMENT MARKET COVID-19 IMPACT

6 BRONCHITIS TREATMENT MARKET REVENUE (USD BN), 2019-2027F

7 MARKET INSIGHTS BY TYPE

  • 7.1. Acute Bronchitis
  • 7.2. Chronic Bronchitis

8 MARKET INSIGHTS DRUG CLASS

  • 8.1. Antibiotics
  • 8.2. Anti-inflammatory
  • 8.3. Bronchodilator
  • 8.4. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 9.1. Hospital Pharmacies
  • 9.2. Retail Pharmacies
  • 9.3. Others

10 MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Spain
    • 10.2.5. Italy
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11 BRONCHITIS TREATMENT MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.3. Impact Analysis

12 BRONCHITIS TREATMENT MARKET OPPORTUNITIES

13 BRONCHITIS TREATMENT MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

  • 16.1. Competitive Landscape
    • 16.1.1. Porter's Five Forces Analysis

17 COMPANY PROFILED

  • 17.1. AstraZeneca PLC
  • 17.2. Novartis AG
  • 17.3. GlaxoSmithKline PLC
  • 17.4. Dr. Reddy's Laboratories Ltd
  • 17.5. Sanofi SA
  • 17.6. Boehringer Ingelheim International GmbH
  • 17.7. Pfizer Inc.
  • 17.8. Melinta Therapeutics
  • 17.9. Lupin Limited
  • 17.10. Cadila Healthcare Limited

18 DISCLAIMER